Probing microglial activation in psychosis.

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 50

Inclusion Criteria

-Men and women
-Mini Mental State score >27
-Written informed consent of the subject;Specific for patients with psychotic symptoms:
- Presence of schizophrenic and psychotic symptoms according to DSM-IV criteria using the Comprehensive Assessment of Symptoms and History interview (CASH) (N.B. Official DSM-IV diagnosis can be performed six months after onset of symptoms.)

Exclusion Criteria

Healthy controls:
-History of psychiatric or neurological illness based (DSM-IV criteria)
-First-degree relatives with a family history of schizophrenia or schizophrenia spectrum disorders
-Any neurological disorder
-(History of) Alcohol and/or drug abuse (DSM-IV criteria)
-Any clinical significant abnormality of any clinical laboratory test, including drug screening (but positive cannabis test is allowed for patients)
-Any condition that may interfere with MRI scanning, e.g. metal objects in or around the body or claustrophobia
-Pregnancy;Specific for medicated patients with psychotic symptoms:
- Any neurological disorder;Specific for first episode medication-naive patients with psychotic symptoms:
- Use of antipsychotics
- Treating physician does not support a delay of medication for the patient (from a clinical perspective)
- Risk that the patient causes serious harm to oneself or others
- Clinical Global Impressions Severity (CGI-S) score 5 or higher
- Psychotic symptoms are too severe to participate (based on CGI-S score and clinical view of treating physician)

Study & Design

Study Type: Observational invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The primary outcome is the difference in [11C]-R-PK11195 binding potential<br /><br>(BPND) in various brain regions between subjects with psychosis and healthy<br /><br>controls. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>The secondary outcome is the relation between microglial activation and other<br /><br>markers for neuronal damage and inflammation. This includes grey matter loss,<br /><br>white matter damage and loss of functional connectivity between brain regions,<br /><br>as well as inflammatory cytokine concentrations in serum. </p><br>